Hello. Welcome to the IQ and Ammuno Oncology in intelligence zone. My name is Rich Carvahal. I'm a medical oncologist. I'm the deputy physician in chief here at the Northwell Health Cancer Institute. Just in the way of background, uh, I'm a medical oncologist. My disease uh focus has been melanoma with a particular focus in rare subsets of melanomas like mucosal melanoma and uveal melanoma. Um, I began my career at Memorial Sloan Kettering Cancer Center, uh, where I spent a lot of time in early phase drug development, uh, and by the time I left there I was leading the, uh, phase one program there. I left for Columbia in 2014 where I took on the role as the director of the melanoma skin cancer program as well as the director of the phase one program there and had the opportunity to build the melanoma skin program, build the clinical research program focusing on early phase trials. And as you might imagine over the past several decades with the um the really immense um incredible advances in our understanding of the immunobiology of cancer, um, with the developments in terms of novel therapeutics, a lot of the work that I, I did in that early phase space was, uh, in the development of novel immunotherapies, um, major focus on uh checkpoint blockade as well as other agents. And so, um, I joined Northwell about a year and a half ago now in this role of deputy physician chief overseeing hematology oncology for the system, um, which extends to Westchester, Manhattan, Queens, Staten Island, and Long Island, um, and here it's been an incredible opportunity not just to grow the clinical enterprise but also build a scientific program in collaboration with Cold Spring Harbor. Uh, as, uh, many of you know, Colspring Harbor is one of the basic NCI designated cancer centers led now by David Tuvison. And Northwell entered into a strategic alliance in 2015 with Cold Spring Harbor with a dual intent to drive the scientific mission of Northwell and help translate some of the signs from Cold Spring Harbor into the clinic, very bidirectional. Uh, with clinical specimens, clinical annotation, material going to Cold Spring Harbor, uh, the development of novel, um, concepts, novel therapy, um, bringing forth the foundational sign from Cold Spring Harbor into the patients. So it's, it's been, uh, thus far an incredible, incredible time.
Presenter
